<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00085917</url>
  </required_header>
  <id_info>
    <org_study_id>040187</org_study_id>
    <secondary_id>04-I-0187</secondary_id>
    <nct_id>NCT00085917</nct_id>
  </id_info>
  <brief_title>Peginterferon Alpha-2a and Ribavirin to Treat Hepatitis C in HIV-infected Patients</brief_title>
  <acronym>PIFNPK</acronym>
  <official_title>A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Twice-Weekly Peginterferon Alpha 2a and Ribavirin Induction Therapy for Chronic Hepatitis C in Patients Who Are Coinfected With HIV-1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and effectiveness of combination therapy with&#xD;
      peginterferon alpha-2a and ribavirin for treating hepatitis C virus (HCV) infection in&#xD;
      HIV-infected patients. Peginterferon alpha with ribavirin is the therapy of choice for people&#xD;
      with HCV alone. Peginterferon alpha-2a is a compound that results from attaching a&#xD;
      polyethylene glycol molecule to interferon alpha-2a. This compound stays in the blood longer&#xD;
      than unmodified interferon alpha-2a, causing a higher blood concentration and thus&#xD;
      maintaining greater activity against the hepatitis C virus.&#xD;
&#xD;
      HIV-infected patients 18 years of age and older with chronic hepatitis C infection and a&#xD;
      viral load greater than 2000 copies/mL may be eligible for this 2-1/2 year study. Candidates&#xD;
      are screened with a medical history and physical examination, blood and urine tests, eye&#xD;
      examination, chest x-ray, electrocardiogram (EKG), liver ultrasound, and pregnancy test in&#xD;
      women who are able to become pregnant. If a recent liver biopsy is not available, this test&#xD;
      is done to determine the type and severity of liver disease. The patient is given a sedative&#xD;
      before the procedure. Then, the skin in the area over the biopsy site is numbed with a local&#xD;
      anesthetic and a needle is inserted rapidly into and out of the liver to obtain a small&#xD;
      tissue sample. The patient remains in the hospital overnight for monitoring.&#xD;
&#xD;
      Participants begin treatment with injections under the skin of peginterferon alpha-2a and&#xD;
      ribavirin pills by mouth on study day 0. Peginterferon is given either once or twice a week&#xD;
      for 4 weeks and then once a week for 44 weeks. Ribavirin is given daily. In addition,&#xD;
      patients continue to take all other medications prescribed by their doctor. Clinic visits are&#xD;
      scheduled for the following procedures:&#xD;
&#xD;
        -  Days 1, 3, 4, 7, 10 and weeks 2, 3, and 4 - Blood tests for safety measures and to&#xD;
           measure blood levels of HIV and HCV.&#xD;
&#xD;
        -  Weeks 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 - Blood and urine tests to determine the&#xD;
           side effects of treatment and its effect on the HCV infection. In addition, eye&#xD;
           examinations are done every 3 months, and pregnancy and thyroid function tests are done&#xD;
           several times during the treatment period.&#xD;
&#xD;
        -  Week 48 or end of treatment - Treatment stops after 48 weeks. At this time, or earlier&#xD;
           for those who do not complete the 48 weeks, patients return to the clinic for a chest&#xD;
           x-ray, EKG, blood tests, and abdominal ultrasound. Patients are hospitalized for a&#xD;
           repeat liver biopsy.&#xD;
&#xD;
        -  Weeks 52, 56, 64 and 72 - Blood and urine tests to determine the side effects of&#xD;
           treatment and its effect on the HCV infection, and a urine pregnancy test in women.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hepatitis C infection occurs in one-third of all HIV-infected individuals. Liver disease has&#xD;
      become more significant among patients coinfected with HIV and HCV. Several studies have&#xD;
      shown that coinfected individuals develop earlier and more severe liver disease. Pegylated&#xD;
      interferon alpha with ribavirin has become the therapy of choice among people with HCV alone.&#xD;
      This is a randomized controlled study to address the safety and efficacy of a 4 week&#xD;
      induction therapy consisting of twice-weekly pegylated interferon alpha-2a and daily&#xD;
      ribavirin on HIV-1 and hepatitis C coinfected individuals. Twenty-two patients who are&#xD;
      infected with both HIV and HCV and who also have evidence of chronic hepatitis will be&#xD;
      randomized to receive peginterferon alpha-2a either twice weekly or once weekly for four&#xD;
      weeks. They will then continue with standard weekly peginterferon for 44 more weeks. The&#xD;
      patients will receive standard daily dose of ribavirin during the entire 48 weeks. These&#xD;
      patients will be monitored for peginterferon level, HCV viral load, HIV viral load and CD4&#xD;
      counts and undergo a baseline liver biopsy and another at the end of 72 weeks. The results of&#xD;
      the study will enable us to better delineate the efficacy of twice weekly peginterferon&#xD;
      induction therapy in suppressing the hepatitis C virus in the first 4 weeks of the therapy.&#xD;
      Since viral suppression for hepatitis C in the early phase of the combination treatment has&#xD;
      predictive values for long term eradication of the virus, a therapy that improves early viral&#xD;
      suppression may improve the long term cure rate. This will be especially important given the&#xD;
      current low cure rate of HCV among HIV coinfected individuals.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Sustained Virologic Response (SVR)</measure>
    <time_frame>72 weeks</time_frame>
    <description>SVR [ Sustained virological response] SVR was defined as HCV RNA levels below the limit of detection 24 weeks after the end of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Normalization of Liver Enzymes</measure>
    <time_frame>week 24, week 48, week 72</time_frame>
    <description>normalization of liver enzymes :Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) Alanine aminotransferase (ALT): Normal 6 - 41 U/L Aspartate aminotransferase (AST) : Normal 9 - 34 U/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>48 weeks</time_frame>
    <description>Adverse Events&#xD;
- Anemia, Neutropenia and Psychiatric adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Hepatitis C</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Standard dose arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pegylated interferon alfa -2a STANDARD DOSE Pegasys 180ug/week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Double dose arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Double dose pegylated interferon with weight based Ribavirin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Double dose pegylated interferon with weight based Ribavirin</intervention_name>
    <description>pegylated interferon alfa -2a 180ug/twice weekly and weight based ribavirin for 4 weeks then pegylated interferon alfa -2a 180ug/ weekly for the remainder of the treatment</description>
    <arm_group_label>Double dose arm</arm_group_label>
    <other_name>Pegasys</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>standard dose pegylated interferon alfa -2a and ribavirin</intervention_name>
    <description>pegylated interferon alfa -2a 180ug weekly and weight based ribavirin for duration of the treatment</description>
    <arm_group_label>Standard dose arm</arm_group_label>
    <other_name>pegasys</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA&#xD;
&#xD;
          -  Age greater than or equal to18 years.&#xD;
&#xD;
          -  Documentation of HIV-1 infection by licensed ELISA test and confirmed by a Western&#xD;
             Blot.&#xD;
&#xD;
          -  Documentation of Hepatitis C infection by demonstration of a positive test for&#xD;
             hepatitis C antibody and on HCV RNA level of 2000 or greater.&#xD;
&#xD;
          -  Histopathologic features consistent with chronic hepatitis C on liver biopsy at the&#xD;
             time of enrollment. A liver biopsy done for a subject within a year prior to his or&#xD;
             her participation may be used as the baseline biopsy.&#xD;
&#xD;
          -  Patients with CD4+ cell count greater than 200 cells/mm3 or CD4+ cell percentage&#xD;
             greater than 14%.&#xD;
&#xD;
          -  Ability to sign informed consent and willingness to comply with the study requirements&#xD;
             and clinic policies.&#xD;
&#xD;
          -  Serum phosphorus greater than or equal to 2.2 mg/dL and less than or equal to 4.4&#xD;
             (normal range NIH 2.3-4.3 mg/dL).&#xD;
&#xD;
          -  Neutrophil count greater than or equal to 1000 cells/mm3.&#xD;
&#xD;
          -  Platelets greater than or equal to 50,000/ mm3.&#xD;
&#xD;
          -  Hemoglobin greater than or equal to 10.5 mg/dL.&#xD;
&#xD;
          -  ALT less than 7 X the NIH upper limit of normal.&#xD;
&#xD;
          -  Serum lipase less than 1.5 X the NIH upper limit of normal.&#xD;
&#xD;
          -  Not pregnant or breast-feeding. Pregnancy test must be negative within two weeks prior&#xD;
             to dosing with study medications.&#xD;
&#xD;
          -  If the patient is able to become pregnant then she must use two effective methods of&#xD;
             contraception during the study. Effective contraceptive methods include abstinence,&#xD;
             surgical sterilization of either partner, barrier methods such as diaphragm, condom,&#xD;
             cap or sponge, or use of hormonal contraception with an anti-HIV regimen that will not&#xD;
             alter metabolism of hormonal contraception. This is advised on the basis of using&#xD;
             ribavirin, which may have a potential teratogenic effect in pregnant women.&#xD;
&#xD;
          -  Need to have a primary doctor outside of OP8 or as part of the OP8 training clinic who&#xD;
             will be taking care of the patients for their HIV infection and liver disease.&#xD;
&#xD;
          -  Willing to designate a person for durable power of attorney on the NIH form for&#xD;
             medical research and medical care purposes at the NIH Clinical Center.&#xD;
&#xD;
          -  Able to learn to safely inject medication subcutaneously or be able to find another&#xD;
             person or a clinic to inject for him/her.&#xD;
&#xD;
        EXCLUSION CRITERIA&#xD;
&#xD;
          -  Patient should not be on other experimental therapies during their participation in&#xD;
             this protocol.&#xD;
&#xD;
          -  Patients should not have used interferon or peginterferon previously for the treatment&#xD;
             of hepatitis C&#xD;
&#xD;
          -  Liver histology which, in the opinion of Clinical center pathologist, is consistent&#xD;
             with any other co-existent cause of chronic liver disease as defined as chronic&#xD;
             hepatitis B with positive HBSag, autoimmune hepatitis with a positive ANA greater than&#xD;
             1 unit or positive anti mitochondrial antibody greater than 1 unit, cholestatic&#xD;
             disease with persistent elevation of Alkaline phosphatase, primary biliary cirrhosis&#xD;
             or sclerosing cholangitis, Wilson's disease, alpha-1-antitrypsin deficiency,&#xD;
             steatohepatitis (alcohol or non alcoholic) with marked steatosis, many Mallory bodies,&#xD;
             or extensive zone 3 periportal fibrosis.&#xD;
&#xD;
          -  Hemochromatosis or secondary iron overload as defined by (1) an elevated serum&#xD;
             ferritin or an iron saturation (serum iron/IBC X 100%) of greater than 50% and (2)&#xD;
             presence of 3+ or more stainable Iron on liver biopsy according to the study&#xD;
             pathologist or a history of previous phlebotomy for Iron overload will undergo HFE&#xD;
             genetic counseling and those with a positive HFE genetic test demonstrating&#xD;
             homozygosity for C282Y and H63D are not eligible. Those who have compound&#xD;
             heterozygosity to C282Y and H63D are also not eligible.&#xD;
&#xD;
          -  Child Turcotte Pugh score greater than 7.&#xD;
&#xD;
          -  PT-INR greater than 2 or history of hemophilia.&#xD;
&#xD;
          -  Organ transplant recipient.&#xD;
&#xD;
          -  Creatinine clearance less than 50 mL/min.&#xD;
&#xD;
          -  Elevated alpha-fetoprotein level (greater than 100 ng/mL).&#xD;
&#xD;
          -  Coexisting neoplastic disease except for Kaposi's Sarcoma, any non-metastatic skin&#xD;
             cancer that has been resected, non-metastatic cervical or anal cancer that has been&#xD;
             resected.&#xD;
&#xD;
          -  Severe cardiac or pulmonary decompensation.&#xD;
&#xD;
          -  Severe psychiatric disorder that would interfere with the adherence to protocol&#xD;
             requirements.&#xD;
&#xD;
          -  Preexisting autoimmune disorders including inflammatory bowel diseases, psoriasis, and&#xD;
             optic neuritis.&#xD;
&#xD;
          -  Preexisting uncontrolled seizure disorder.&#xD;
&#xD;
          -  Preexisting pancreatitis.&#xD;
&#xD;
          -  Severe retinopathy as determined by the ophthalmologist.&#xD;
&#xD;
          -  Hemoglobinopathy.&#xD;
&#xD;
          -  Currently taking didanosine as part of antiretroviral regimen.&#xD;
&#xD;
          -  Direct bilirubin greater than 0.6 mg/dL.&#xD;
&#xD;
          -  Using long-term systemic corticosteroids, immunosuppressives, or cytotoxic agents&#xD;
             within 60 days of enrollment into the trial.&#xD;
&#xD;
          -  Chronic viral hepatitis of any other etiology other than hepatitis C.&#xD;
&#xD;
          -  Active systemic infections other than hepatitis C and HIV.&#xD;
&#xD;
          -  Liver disease caused by reasons other than hepatitis C like HBV, HDV, Wilson's,&#xD;
             hemochromatosis, autoimmune hepatitis (ANA greater than 1 unit) except history of&#xD;
             drug-associated hepatitis with discontinuation of the causative agent.&#xD;
&#xD;
          -  Hepatic mass suggestive of hepatocellular carcinoma as detected by ultrasound scan.&#xD;
&#xD;
          -  Alcohol or substance abuse that potentially could interfere with patient compliance.&#xD;
&#xD;
          -  History of esophageal varices.&#xD;
&#xD;
          -  Any systemic illness that will make it unlikely that the subject will be able to&#xD;
             return to NIH for the required study visits.&#xD;
&#xD;
          -  Evidence of gastrointestinal malabsorption or chronic nausea or vomiting.&#xD;
&#xD;
          -  Male partners of pregnant women.&#xD;
&#xD;
          -  Pregnant women.&#xD;
&#xD;
          -  Breastfeeding women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shyam Kottilil</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Allergy and Infectious Diseases (NIAID)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Alter MJ, Mast EE. The epidemiology of viral hepatitis in the United States. Gastroenterol Clin North Am. 1994 Sep;23(3):437-55. Review.</citation>
    <PMID>7989088</PMID>
  </reference>
  <reference>
    <citation>Seeff LB, Buskell-Bales Z, Wright EC, Durako SJ, Alter HJ, Iber FL, Hollinger FB, Gitnick G, Knodell RG, Perrillo RP, et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group. N Engl J Med. 1992 Dec 31;327(27):1906-11.</citation>
    <PMID>1454085</PMID>
  </reference>
  <reference>
    <citation>Koretz RL, Abbey H, Coleman E, Gitnick G. Non-A, non-B post-transfusion hepatitis. Looking back in the second decade. Ann Intern Med. 1993 Jul 15;119(2):110-5.</citation>
    <PMID>8512159</PMID>
  </reference>
  <verification_date>June 2011</verification_date>
  <study_first_submitted>June 16, 2004</study_first_submitted>
  <study_first_submitted_qc>June 16, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2004</study_first_posted>
  <results_first_submitted>April 12, 2010</results_first_submitted>
  <results_first_submitted_qc>May 13, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 15, 2011</results_first_posted>
  <last_update_submitted>June 21, 2011</last_update_submitted>
  <last_update_submitted_qc>June 21, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2011</last_update_posted>
  <responsible_party>
    <name_title>Shyamasundaran Kottilil, M.D./National Institute of Allergy and Infectious Diseases</name_title>
    <organization>National Institutes of Health</organization>
  </responsible_party>
  <keyword>Pegasys</keyword>
  <keyword>Ribavirin</keyword>
  <keyword>Early Virological Response</keyword>
  <keyword>Hepatitis C</keyword>
  <keyword>HIV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period was over a period of 3 yrs from 2004 - 2007. Participants were recruited and screened through the OP8 clinic of the NIAID.</recruitment_details>
      <pre_assignment_details>There were no significant events or approaches following participant enrollment prior to group assignments.&#xD;
However if enrolled participants subsequently developed exclusion criteria such as active alcohol or drug abuse, they were excluded from the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Pegasys Single Dose</title>
          <description>pegylated interferon alfa -2a 180 mcg/week and weight based Ribavirin (1000daily for weight&lt;75kg, 1200mg daily for weight &gt;75kg)&#xD;
- Treatment for 48 weeks</description>
        </group>
        <group group_id="P2">
          <title>Pegasys Double Dose</title>
          <description>pegylated interferon alfa -2a 180 mcg/twice week and weight based Ribavirin (1000daily for weight&lt;75kg, 1200mg daily for weight &gt;75kg) for 4 weeks then pegylated interferon alfa -2a 180 mcg/week and weight based Ribavirin (1000daily for weight&lt;75kg, 1200mg daily for weight &gt;75kg) for 44 weeks&#xD;
- Total Treatment for 48 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pegasys Single Dose</title>
          <description>pegylated interferon alfa -2a 180 mcg/week and weight based Ribavirin (1000daily for weight&lt;75kg, 1200mg daily for weight &gt;75kg)&#xD;
- Treatment for 48 weeks</description>
        </group>
        <group group_id="B2">
          <title>Pegasys Double Dose</title>
          <description>pegylated interferon alfa -2a 180 mcg/twice week and weight based Ribavirin (1000daily for weight&lt;75kg, 1200mg daily for weight &gt;75kg) for 4 weeks then pegylated interferon alfa -2a 180 mcg/week and weight based Ribavirin (1000daily for weight&lt;75kg, 1200mg daily for weight &gt;75kg) for 44 weeks&#xD;
- Total Treatment for 48 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="29"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48" spread="6.402"/>
                    <measurement group_id="B2" value="46" spread="5.93"/>
                    <measurement group_id="B3" value="47" spread="6.109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Sustained Virologic Response (SVR)</title>
        <description>SVR [ Sustained virological response] SVR was defined as HCV RNA levels below the limit of detection 24 weeks after the end of treatment.</description>
        <time_frame>72 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pegasys Single Dose</title>
            <description>pegylated interferon alfa -2a 180 mcg/week and weight based Ribavirin (1000daily for weight&lt;75kg, 1200mg daily for weight &gt;75kg)&#xD;
- Treatment for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>Pegasys Double Dose</title>
            <description>pegylated interferon alfa -2a 180 mcg/twice week and weight based Ribavirin (1000daily for weight&lt;75kg, 1200mg daily for weight &gt;75kg) for 4 weeks then pegylated interferon alfa -2a 180 mcg/week and weight based Ribavirin (1000daily for weight&lt;75kg, 1200mg daily for weight &gt;75kg) for 44 weeks&#xD;
- Total Treatment for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Sustained Virologic Response (SVR)</title>
          <description>SVR [ Sustained virological response] SVR was defined as HCV RNA levels below the limit of detection 24 weeks after the end of treatment.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Normalization of Liver Enzymes</title>
        <description>normalization of liver enzymes :Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) Alanine aminotransferase (ALT): Normal 6 - 41 U/L Aspartate aminotransferase (AST) : Normal 9 - 34 U/L</description>
        <time_frame>week 24, week 48, week 72</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pegasys Single Dose</title>
            <description>pegylated interferon alfa -2a 180 mcg/week and weight based Ribavirin (1000daily for weight&lt;75kg, 1200mg daily for weight &gt;75kg)&#xD;
- Treatment for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>Pegasys Double Dose</title>
            <description>pegylated interferon alfa -2a 180 mcg/twice week and weight based Ribavirin (1000daily for weight&lt;75kg, 1200mg daily for weight &gt;75kg) for 4 weeks then pegylated interferon alfa -2a 180 mcg/week and weight based Ribavirin (1000daily for weight&lt;75kg, 1200mg daily for weight &gt;75kg) for 44 weeks&#xD;
- Total Treatment for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Normalization of Liver Enzymes</title>
          <description>normalization of liver enzymes :Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) Alanine aminotransferase (ALT): Normal 6 - 41 U/L Aspartate aminotransferase (AST) : Normal 9 - 34 U/L</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>Adverse Events&#xD;
- Anemia, Neutropenia and Psychiatric adverse events</description>
        <time_frame>48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pegasys Single Dose</title>
            <description>pegylated interferon alfa -2a 180 mcg/week and weight based Ribavirin (1000daily for weight&lt;75kg, 1200mg daily for weight &gt;75kg)&#xD;
- Treatment for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>Pegasys Double Dose</title>
            <description>pegylated interferon alfa -2a 180 mcg/twice week and weight based Ribavirin (1000daily for weight&lt;75kg, 1200mg daily for weight &gt;75kg) for 4 weeks then pegylated interferon alfa -2a 180 mcg/week and weight based Ribavirin (1000daily for weight&lt;75kg, 1200mg daily for weight &gt;75kg) for 44 weeks&#xD;
- Total Treatment for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>Adverse Events&#xD;
- Anemia, Neutropenia and Psychiatric adverse events</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 YEARS</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Pegasys Single Dose</title>
          <description>pegylated interferon alfa -2a 180 mcg/week and weight based Ribavirin (1000daily for weight&lt;75kg, 1200mg daily for weight &gt;75kg)&#xD;
- Treatment for 48 weeks</description>
        </group>
        <group group_id="E2">
          <title>Pegasys Double Dose</title>
          <description>pegylated interferon alfa -2a 180 mcg/twice week and weight based Ribavirin (1000daily for weight&lt;75kg, 1200mg daily for weight &gt;75kg) for 4 weeks then pegylated interferon alfa -2a 180 mcg/week and weight based Ribavirin (1000daily for weight&lt;75kg, 1200mg daily for weight &gt;75kg) for 44 weeks&#xD;
- Total Treatment for 48 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="11"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="11"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="11"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated transaminases</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="11"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression/anxiety</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="11"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small number of enrolled participants</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>John Tierney</name_or_title>
      <organization>RCHSPB</organization>
      <phone>301-451-5136</phone>
      <email>john.tierney@nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

